1） 里見佳昭, 他 : 外科系医師のための腎癌の診断と治療. 日外科系連会誌22 : 125-140, 1997
2） Motzer RJ, et al : Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373 : 1803-1813, 2015
3） Motzer RJ, et al : Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med 378 : 1277-1290, 2018
4） Motzer RJ, et al : Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380 : 1103-1115, 2019
5） Rini BI, et al : Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 380 : 1116-1127, 2019
6） Choueiri TK, et al : Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. N Engl J Med 384 : 829-841, 2021
7） Motzer R, et al : Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. N Engl J Med 384 : 1289-1300, 2021
8） Choueiri TK, et al : Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma. N Engl J Med 391 : 710-721, 2024
9） Tannir NM, et al : Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma : extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 35 : 1026-1038, 2024
10） Motzer RJ, et al : Biomarker analysis from CheckMate 214 : nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. J Immunother Cancer 10 : e004316, 2022
11） Braun DA, et al : Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med 26 : 909-918, 2020
12） Miao D, et al : Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. Science 359 : 801-806, 2018
13） Motzer RJ, et al : Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell 38 : 803-817.e4, 2020
14） Saliby RM, et al : Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell 42 : 732-735, 2024
15） Hage Chehade C, et al : Molecular subtypes as potential biomarkers in renal cell carcinoma. Cancer Cell 42 : 736-738, 2024
16） Jikuya R, et al : Comparative transcriptome atlas as an assistive modality for complex classification of rare kidney cancers. Nat Commun 16 : 10340, 2025
